D-0281-2019 Class II Terminated

Recalled by Upsher Smith Laboratories, Inc. — Maple Grove, MN

FDA drug recall D-0281-2019 was initiated by Upsher Smith Laboratories, Inc. on Sep 19, 2018 and is designated Class II. Reason for recall: Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product. The recall status is terminated (terminated Sep 30, 2020). Affected quantity: 29,080 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 31, 2018
Initiation Date
Sep 19, 2018
Termination Date
Sep 30, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
29,080 bottles

Product description

Bumetanide Tablets, USP, 2 mg, 100-count bottle, Rx only, Manufactured by: Upser-Smith Laboratories, LLC, Maple Grove, MN 55369, NDC 0832-0542-11

Reason for recall

Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.

Distribution pattern

Nationwide USA, Puerto Rico and Guam

Code information

Lot#: 372461, 372952, 372954, 372955, 373624, 374539, Exp 3/31/2020; 375719, 375721, 376684, Exp 5/31/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0281-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0281-2019. Report a data issue: hello@regdatalab.com.